Core Viewpoint - The company Yifan Pharmaceutical has successfully completed the first shipment of its innovative drug F-627 to the U.S. market, marking a significant milestone in its international expansion [1] Group 1: Product Launch - F-627, also known as Ryzneuta, is the world's first third-generation long-acting G-CSF drug for increasing white blood cell counts [1] - The drug has received approval for sale in multiple regions, including China, the U.S., the EU, and Brazil [1] Group 2: Market Expectations - Based on current order conditions, the company anticipates shipping approximately 40,000 units overseas by 2025 [1] - The drug has been successfully included in China's medical insurance directory following negotiations in 2023 [1]

Core Viewpoint - The announcement details the pledge and release of shares by Cheng Xianfeng, the controlling shareholder of Yifan Pharmaceutical Co., Ltd, indicating changes in shareholding structure and potential implications for the company's stock performance [2][4]. Share Pledge Details - Cheng Xianfeng pledged 5.24% of his shares, amounting to 2.14% of the company's total share capital, starting from May 25, 2025 [2]. - The pledge was made to China Galaxy Securities Co., Ltd [2]. Share Release Details - Cheng Xianfeng released 22,000,000 shares, which represents 4.43% of his total holdings and 1.81% of the company's total share capital, effective from May 27, 2025 [2]. - The shares were also released from pledge to China Galaxy Securities Co., Ltd [2]. Cumulative Pledge Situation - As of the announcement date, Cheng Xianfeng and his concerted actors have a total of pledged shares, with the cumulative pledged amount being significant [2]. - The report indicates the proportion of pledged shares relative to total holdings and the company's total share capital [2][4].

证券代码：002019 证券简称：亿帆医药 公告编号：2025-036 亿帆医药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、股东股份累计被质押的情况 截至本公告披露日，程先锋先生及其一致行动人所持股份质押情况如下： | 股东名称 | 持股数 量 | 持股比 | 累计质押 数量 | 占其所 持股份 | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占公司总 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | 例 | | | 股本比例 | 限售和冻结 | 押股份 | 限售和冻结 | 押股份 | | | （股） | | （股） | 比例 | | | | | | | | | | | | | 数量（股） | 比例 | 数量（股） | 比例 | | 程先锋 | 496,526, | 40.82 | 69,500,00 | 14.00% | ...

Core Viewpoint - The termination of the merger between New Nuo Wei and Shiyao Baike Bio marks a significant setback for New Nuo Wei's innovative drug strategy, leading to a financial crisis due to high R&D costs and declining cash flow [2][10]. Financial Performance - New Nuo Wei's net profit for 2024 was 53.73 million yuan, a decrease of 87.63% year-on-year, and in Q1 2025, the net profit loss was 26.90 million yuan, a decline of 134.03% [10]. - The company's operating cash flow for 2024 was -1.235 billion yuan, marking its first instance of cash flow loss, with Q1 2025 still showing a negative cash flow of -86.80 million yuan [10][11]. - The total revenue for New Nuo Wei in Q1 2025 was 472 million yuan, a year-on-year decrease of 9.94%, while the total revenue for 2024 was 1.981 billion yuan, down 21.98% [15]. Product Performance - The core product "Jin You Li" (long-acting G-CSF drug) saw a dramatic revenue decline, with projected 2024 revenue of 922 million yuan, down from 2.316 billion yuan in 2023 [3][4]. - The average selling price of "Jin You Li" dropped from 1,349.22 yuan per unit in 2022 to 1,053.12 yuan per unit by mid-2024 [4][5]. - Sales volume for "Jin You Li" in the first half of 2024 was 87.39 million units, compared to 203.52 million units in 2023 [5]. Market Competition - The market for long-acting G-CSF drugs has intensified, with New Nuo Wei's "Jin You Li" facing competition from multiple new entrants, increasing the competitive landscape from six to nine major players [4][6]. - The reliance on a single product for revenue generation poses a significant risk, as "Jin You Li" accounted for over 97% of Shiyao Baike's income [3][6]. Strategic Implications - The failed merger was intended to provide stable income and cash flow to support New Nuo Wei's R&D investments in its subsidiary, Jushi Bio, which is currently under financial strain [10]. - The ongoing high R&D expenditures have significantly impacted New Nuo Wei's profitability, with a gross margin of 41.97% in 2024, down 3.36 percentage points year-on-year [15].

Group 1 - The company has approved a cash dividend distribution plan for the year 2024, proposing to distribute 1 RMB per 10 shares to all shareholders, totaling approximately 121.64 million RMB [1][2] - The distribution will be based on the company's total share capital of 1,216,390,085 shares, excluding repurchased shares, with adjustments made if the total share capital changes before the distribution [1][2] - The dividend tax rates will vary for different types of shareholders, with specific provisions for Hong Kong investors and domestic investors holding different classes of shares [1][2] Group 2 - The record date for the dividend distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [2] - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies or other custodial institutions [2] - The company assumes all legal responsibilities and consequences for any insufficient cash dividends distributed [2]

035 证券代码：002019 证券简称：亿帆医药 公告编号：2025- 4、本次实施分派方案距股东会审议通过的时间未超过两个月。 二、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本剔除已回购股份0股 后的1,216,390,085股为基数，向全体股东每10股派1.000000元人民币现金（含税； 扣税后，通过深股通持有股份的香港市场投资者（特别说明：请上市公司根据自 身是否属于深股通标的证券，确定权益分派实施公告保留或删除该类投资者）、 境外机构（含QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每10 股派0.900000元；持有首发后限售股、股权激励限售股及无限售流通股的个人股 息红利税实行差别化税率征收，本公司暂不扣缴个人所得税，待个人转让股票时， 根据其持股期限计算应纳税额【注】；持有首发后限售股、股权激励限售股及无 亿帆医药股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）2024年年度权益分派方案已获 2025年5月20日召开的2 ...

法律意见书 根据《中华人民共和国公司法》（下称《公司法》）、《中华人民共和国证 券法》（下称《证券法》）、中国证券监督管理委员会（下称"中国证监会"） 《上市公司股东会规则》（下称《股东会规则》）以及《亿帆医药股份有限公司 公司章程》（下称《公司章程》）等有关规定，安徽天禾律师事务所接受亿帆医 药股份有限公司（下称"亿帆医药"或"公司"）委托，指派王炜、罗明伟律师 （下称"天禾律师"）出席公司 2024 年年度股东会（下称"本次股东会"）， 对本次股东会相关事项进行见证，并出具法律意见。 本法律意见书是天禾律师根据对有关本次股东会事实的了解及对我国现行 法律、法规和规范性文件的理解而做出的。 天禾律师同意将本法律意见书作为本次股东会的必备文件予以公告并依法 对所出具的法律意见书承担责任。 天禾律师根据有关法律、法规的要求，按照律师行业公认的业务标准、道德 规范和勤勉尽责的精神，对本次股东会的召集和召开程序、出席会议人员的资格、 表决程序及其他相关法律问题发表法律意见如下： 一、本次股东会的召集与召开程序 （一）2025 年 4 月 24 日，公司召开第八届董事会第十六次会议，通过了《关 于召开 2024 年年 ...

亿帆医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东会无否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-034 （一）会议召开情况 一、会议召开和出席情况 1、会议召开的日期、时间 现场会议召开的时间：2025 年 5 月 20 日下午 1:30 起 网络投票的时间：2025 年 5 月 20 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 20 日上午 9:15 至 9:25，9:30 至 11:30，下午 13:00 至 15:00； 通过深圳证券交易所互联网投票系统进行网络投票，开始时间为 2025 年 5 月 20 日上午 9:15 至下午 15:00。 2、现场会议召开地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口， 合肥亿帆生物制药有限公司会议室 3、召集人：公司董事会 4、会议方式：本次会议采取现场投票和网络投票相结合的方式 5、会议主持人：董事长程先锋 ...

Group 1 - The core point of the news is the introduction of an executive order by President Trump aimed at lowering prescription drug prices in the U.S. through a "most-favored-nation pricing" model, aligning local drug prices with those in other developed countries [1][5] - Following the announcement, the domestic innovative drug sector in China experienced a significant market reaction, with related ETFs rising nearly 2% after an initial drop [1][5] - The executive order is perceived to favor generic drugs and biosimilars, potentially lowering entry barriers and increasing competition in the U.S. market [6][7] Group 2 - From 2007 to 2023, 350 innovative drugs from 177 Chinese pharmaceutical companies were studied in 691 clinical trials in the U.S., with 7 products approved for market [2][4] - Notable approved Chinese innovative drugs include BeiGene's BTK inhibitor, Legend Biotech's CAR-T therapy, and Junshi Biosciences' PD-1 inhibitor, with significant sales growth reported for these products in the U.S. market [4][5] - The impact of the drug pricing executive order on Chinese innovative drug companies is mixed; while some companies may face pressure on pricing, others may benefit from reduced competition in the generic drug space [7][8] Group 3 - Investment sentiment towards Chinese innovative drug companies remains cautiously optimistic, with some investors believing the impact of the pricing policy may not be as severe as anticipated [7][8] - The market share of U.S. sales is significant for many Chinese companies, with one leading company reporting a 107.5% year-on-year increase in sales for its core product in the U.S. [4][8] - The overall effect of the executive order on the pharmaceutical landscape is still uncertain, with companies advised to closely monitor developments [8][9]

Core Viewpoint - Brother Technology Co., Ltd. is planning to issue A-shares to specific investors to raise funds primarily for expanding its production capacity of iodinated contrast agents, with a focus on addressing market demand and potential risks associated with capacity utilization and economic performance [1][2][3]. Group 1: Company Overview - Brother Technology Co., Ltd. was established on March 19, 2001, with a registered capital of 1,063.70 million RMB [14]. - The company operates in the pharmaceutical and specialty chemicals sectors, focusing on the production of iodinated contrast agents and other related products [14]. - The company is headquartered in Haining, Zhejiang Province, China, and is listed on the Shenzhen Stock Exchange under the stock code 002562 [14]. Group 2: Fundraising and Investment Plans - The company plans to raise up to 4,367.50 million RMB through the issuance of A-shares, with the funds allocated primarily for a project to produce 1,150 tons of iodinated contrast agents, including 600 tons of iodinated contrast agent raw materials [9][10]. - The total investment for the iodinated contrast agent project is estimated at 6,901.86 million RMB, with 5,600.00 million RMB of the raised funds designated for this project [10]. - The company has conducted feasibility studies and market analysis to ensure the viability of the investment projects [1][2]. Group 3: Risks and Challenges - The company faces risks related to the absorption of new production capacity, as the expansion from 100 tons to 700 tons of iodinated contrast agent raw materials may lead to overcapacity if market demand does not meet expectations [1][2]. - There are concerns regarding the economic performance of previous fundraising projects, particularly the "Phenol Phase II Project," which may not achieve the anticipated economic benefits [2][3]. - The company is also exposed to industry cyclicality, price fluctuations of raw materials, and regulatory uncertainties that could impact its operational performance and profitability [4][5][6].